IFT52: A Potential Drug Target and Biomarker (G51098)

Target Name: IFT52

NCBI ID: G51098

IFT52

IFT52: A Potential Drug Target and Biomarker

IFT52 (IFT52_HUMAN), a protein expressed in human tissues, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and expression pattern make IFT52 an attractive target for researchers to study and develop new treatments.

IFT52 is a member of the IFT family, which includes several structurally similar proteins that are involved in various cellular processes, including cell adhesion, migration, and invasion. IFT52 is unique in that it is expressed in human tissues, making it a valuable resource for researchers studying human diseases.

One of the key challenges in studying IFT52 is its complex structure. IFT52 is a transmembrane protein that is expressed in various tissues in the body, including the brain, pancreas, and gastrointestinal tract. Its structure is such that it is difficult to study using traditional techniques such as cell-based assays or recombinant proteins.

However, researchers have been able to study IFT52 using a technique called yeast two-hybrid assays. This technique allows researchers to study protein-protein interactions in a high-throughput manner, providing insights into IFT52's structure and function.

IFT52 has been shown to play a role in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, IFT52 has been shown to be involved in cell migration, invasion, and angiogenesis, which are critical processes that contribute to tumor growth and progression.

In neurodegenerative disorders, IFT52 has been shown to be involved in the development and progression of neurodegeneration. For example, studies have shown that IFT52 is expressed in the brains of individuals with Alzheimer's disease, and that its levels are correlated with the severity of neurodegeneration.

In autoimmune diseases, IFT52 has been shown to play a role in the development and progression of autoimmune diseases. For example, IFT52 has been shown to be involved in the development of rheumatoid arthritis, and that its levels are correlated with the severity of joint inflammation.

Despite these promising findings, much work remains to be done in order to fully understand the role of IFT52 in disease. Researchers are still working to develop new techniques for studying IFT52, and to identify new potential drug targets.

In conclusion, IFT52 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its unique structure and expression pattern make it an attractive resource for researchers studying human diseases. Further research is needed to fully understand the role of IFT52 in disease, and to develop new treatments.

Protein Name: Intraflagellar Transport 52

Functions: Involved in ciliogenesis as part of a complex involved in intraflagellar transport (IFT), the bi-directional movement of particles required for the assembly, maintenance and functioning of primary cilia (PubMed:27466190). Required for the anterograde transport of IFT88 (PubMed:27466190)

The "IFT52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets